Page last updated: 2024-09-05

dabigatran and Peripheral Arterial Disease

dabigatran has been researched along with Peripheral Arterial Disease in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Di Fusco, M; Friend, K; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Thomas, L; Yuce, H1
Baser, O; Di Fusco, M; Friend, K; Gupta, K; Hamilton, M; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Steffel, J1
Bangdiwala, SI; Berwanger, O; Biccard, BM; Botto, F; Chaudhry, NK; Connolly, SJ; de Nadal, M; Devereaux, PJ; Duceppe, E; Eikelboom, JW; Erb, J; Franzosi, MG; Guyatt, G; Hoeft, A; Iglesias, PP; Kearon, C; Magloire, P; Mayosi, B; Meyhoff, CS; Neary, J; Pettit, S; Rahate, PV; Rao, M; Rao-Melacini, P; Rodseth, R; Sessler, DI; Sharma, M; Srinathan, SK; Szczeklik, W; Tandon, V; Villar, JC; Vincent, J; Xavier, D; Yusuf, S1
Gottsäter, A1

Trials

1 trial(s) available for dabigatran and Peripheral Arterial Disease

ArticleYear
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
    Lancet (London, England), 2018, 06-09, Volume: 391, Issue:10137

    Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Omeprazole; Perioperative Period; Peripheral Arterial Disease; Placebo Effect; Proton Pump Inhibitors; Stroke; Thrombosis; Treatment Outcome; Troponin; Venous Thromboembolism

2018

Other Studies

3 other study(ies) available for dabigatran and Peripheral Arterial Disease

ArticleYear
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
    The American journal of cardiology, 2021, 06-01, Volume: 148

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Coronary Artery Disease; Dabigatran; Embolism; Female; Health Care Costs; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Peripheral Arterial Disease; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United States; Warfarin

2021
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
    The American journal of medicine, 2018, Volume: 131, Issue:9

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Myocardial Infarction; Peripheral Arterial Disease; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin

2018
[NOAC in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease].
    Lakartidningen, 2018, 12-04, Volume: 115

    Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Cardiovascular Diseases; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Myocardial Infarction; Myocardial Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Sweden; Thiazoles

2018